UTHR stock forecast, quote, news & analysis
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs... Show more
United Therapeutics (UTHR) Stock Analysis: Pipeline Catalysts Drive Momentum
Key Takeaways
- United Therapeutics (UTHR) has shown resilience in recent trading sessions amid clinical advancements and upcoming earnings.
- FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for miroliverELAP® bolsters the xenotransplantation pipeline.
- New data presented at ISHLT 2026 highlights progress in pulmonary hypertension (PH) detection and lung therapies.
- Insider transactions occurred, but analyst consensus remains bullish with an average price target above current levels.
- Q1 2026 earnings due soon, with expectations for continued revenue growth from core PAH (pulmonary arterial hypertension) products.
- Strong balance sheet with no debt supports ongoing R&D investments.
Current Market Snapshot
In recent weeks, United Therapeutics (UTHR) stock has maintained upward momentum, trading near the upper end of its 52-week range amid positive investor sentiment toward its innovative pipeline in rare pulmonary diseases and beyond. The shares have benefited from clinical progress and anticipation surrounding quarterly results, reflecting confidence in the company's leadership in therapies for pulmonary arterial hypertension and emerging indications like idiopathic pulmonary fibrosis (IPF). Broader biotech sector trends and macroeconomic stability have also supported steady volume and price appreciation, positioning UTHR as a standout performer in recent market cycles.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 performers from over 350 AI trading bots that analyze thousands of tickers across diverse strategies, timeframes, and market conditions. These bots deliver real-time signals for copy trading, featuring annualized returns ranging from 23% to over 160%, win rates of 51% to 88%, and profit factors up to 11.7. Styles vary from multi-agent trend followers on 15-minute charts to swing traders with take-profit/stop-loss corridors on 60-minute intervals, targeting sectors like semiconductors, space stocks, industrials, and ETFs. High performers include bots with 163% returns on volatility plays (e.g., USAR, SMR) and 127% on space imaging tickers, often with profit-to-drawdown ratios exceeding 10. Ideal for volatile markets, they adapt via risk-managed virtual and brokerage agents. Explore these top bots to enhance your trading edge.
Recent Developments Driving UTHR Price Action
United Therapeutics has seen several key updates in the past 30 days that have shaped its stock performance, balancing pipeline optimism with routine corporate matters. On April 8, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to miroliverELAP® for acute liver failure, accelerating development of this xenotransplantation therapy derived from genetically modified pig livers. This milestone underscores UTHR's push into organ replacement solutions, potentially broadening its addressable market beyond pulmonary diseases and contributing to sustained investor interest.
April 20 brought new data presentations at the International Society for Heart and Lung Transplantation (ISHLT) 2026 meeting, including interim PHINDER study analysis identifying non-invasive measures for earlier pulmonary hypertension detection in interstitial lung disease (ILD) patients. Additional insights on lung donor expansion and xenotransplantation further highlighted the company's innovative organ manufacturing capabilities, reinforcing its leadership in transplant technologies and supporting positive sentiment.
Corporate announcements included the April 22 disclosure of Q1 2026 financial results scheduled for May 6, ahead of market open, with a conference call to follow. Analysts anticipate earnings per share around $7.00 and revenue near $800 million, driven by steady demand for Tyvaso® and Remodulin® in PAH treatment. This build-up has kept trading active, though some caution prevails ahead of the report.
Insider activity featured multiple transactions by CEO Martine Rothblatt, including sales totaling millions in early and mid-April under pre-arranged plans, alongside an executive vice president's option exercises. While such moves can introduce short-term pressure, they align with routine liquidity events and have not derailed the uptrend fueled by earlier TETON trial successes in IPF, where Tyvaso met endpoints in March, leading to a 17% gain over the prior period. On April 29, the board announced the retirement of Professor Raymond Dwek at the 2026 annual meeting, a procedural shift with minimal immediate impact.
Overall, these developments have linked to resilient price action, with shares holding near highs despite insider sales, as focus shifts to earnings and regulatory catalysts. Analyst ratings remain predominantly "Buy," with targets averaging $645, signaling confidence in fundamentals.
2026 Outlook and Key Factors to Monitor
As United Therapeutics progresses through 2026, investors should track pipeline milestones, including a planned supplemental New Drug Application (sNDA) for Tyvaso in IPF by year-end half, potentially expanding its label following TETON trials. Double-digit revenue growth is projected from core PAH franchise, bolstered by a debt-free balance sheet exceeding $4.6 billion in cash at year-start. Opportunities lie in xenotransplantation advances like miroliverELAP and lung programs, amid rising demand for organ therapies.
Risks include regulatory hurdles at FDA, competition in pulmonary markets, and manufacturing scalability for bioengineered organs. Macro factors such as healthcare policy shifts and biotech funding environment warrant attention, alongside R&D spend efficiency. Strategic positioning in rare diseases, coupled with transplant innovations, positions UTHR for potential long-term value creation, contingent on clinical and commercial execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
UTHR in +0.34% Uptrend, advancing for three consecutive days on June 12, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where UTHR advanced for three days, in of 315 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where UTHR's RSI Oscillator exited the oversold zone, of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 50 cases where UTHR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
UTHR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UTHR as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
UTHR moved below its 50-day moving average on May 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for UTHR crossed bearishly below the 50-day moving average on May 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTHR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for UTHR entered a downward trend on June 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. UTHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.928) is normal, around the industry mean (144.130). P/E Ratio (20.183) is within average values for comparable stocks, (97.681). Projected Growth (PEG Ratio) (2.236) is also within normal values, averaging (1.601). UTHR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (8.190) is also within normal values, averaging (95.029).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsGeneric